X4 Pharmaceuticals (XFOR) president sells 24,576 shares to cover tax on RSUs

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. president John Volpone reported selling 24,576 shares of common stock on August 12, 2026 at a weighted average price of $4.44 per share, in transactions ranging from $4.33–$4.55, to cover a personal income tax obligation upon settlement of a restricted stock unit award. Following these sales, he directly holds 265,305 shares, of which 193,254 shares represent restricted stock units.

Insider Trade Summary

Net Seller: 24,576 shares

Net Sell 1 txn

Insider Volpone John

Role President

Sold 24,576 shs ($109K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	24,576	$4.4445	$109K

Holdings After Transaction: Common Stock — 265,305 shares (Direct)

Footnotes (3)

1. F1. Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. Of the shares of common stock reported, 193,254 shares represent restricted stock units.

Key Figures

Shares sold: 24,576 shares Weighted average sale price: $4.4445 per share Price range of sales: $4.33–$4.55 per share +2 more

5 metrics

Shares sold 24,576 shares Common stock sold on August 12, 2026 to cover personal income tax obligation

Weighted average sale price $4.4445 per share Weighted average price for 24,576 shares sold, with trades from $4.33 to $4.55

Price range of sales $4.33–$4.55 per share Range of prices for multiple sale transactions included in the reported trade

Shares held after transaction 265,305 shares Direct common stock holdings reported following the August 12, 2026 sales

Restricted stock units within holdings 193,254 shares Portion of post-transaction holdings representing restricted stock units

Key Terms

restricted stock units, weighted average price, personal income tax obligation, open market or private transaction

4 terms

restricted stock units financial

"Of the shares of common stock reported, 193,254 shares represent restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

personal income tax obligation financial

"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

What insider transaction did X4 Pharmaceuticals (XFOR) report for John Volpone?

X4 Pharmaceuticals reported that president John Volpone sold 24,576 shares of common stock on August 12, 2026 at a weighted average price of $4.44 per share, in open-market or private transactions within a stated price range.

Why did John Volpone sell X4 Pharmaceuticals (XFOR) shares in this Form 4?

The filing states the shares were sold to cover personal income tax obligations arising from the settlement of a restricted stock unit award, indicating the disposition was tied to compensation-related tax liabilities rather than a standalone portfolio trade.

What price range did John Volpone receive for sold XFOR shares?

The weighted average sale price was $4.44 per share. Footnotes state the 24,576 shares were sold in multiple transactions at prices ranging from $4.33 to $4.55 per share, inclusive, with detailed breakdowns available on request.

How many X4 Pharmaceuticals (XFOR) shares does John Volpone hold after this sale?

After the reported transactions, John Volpone directly holds 265,305 shares of X4 Pharmaceuticals common stock. Footnote disclosure indicates that 193,254 of these shares represent restricted stock units rather than fully unrestricted shares.

What portion of John Volpone’s XFOR holdings are restricted stock units?

Of John Volpone’s 265,305 post-transaction shares, the filing notes that 193,254 shares represent restricted stock units. This shows a substantial part of his reported position is tied to equity-based compensation that may vest over time.

Was John Volpone’s XFOR share sale executed under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox is marked false, and footnotes do not reference a trading plan. The sale is instead described as covering a personal income tax obligation on a restricted stock unit settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 04:13 PM Accepted by SEC EDGAR 08/13/2026 - 04:13 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Volpone John

(Last) (First) (Middle)

C/O X4 PHARMACEUTICALS INC.

61 NORTH BEACON STREET 4TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
X4 Pharmaceuticals, Inc [ XFOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		S(1)		24,576	D	$4.4445(2)	265,305(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.33 to $4.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Of the shares of common stock reported, 193,254 shares represent restricted stock units.

Remarks:

	/s/ David Kirske, Attorney-In-Fact	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)